Recent And Upcoming FDA Advisory Committee Meetings
Executive Summary
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.
You may also be interested in...
Fluoroquinolones Need REMS With Communication Plan, AdCom Says
Overwhelming votes against existing labels for the antibiotics likely means sponsors and FDA have some safety planning to do.
Sugammadex Review: Has Merck Finally Put Safety Concerns To Rest?
Adequacy of data on risks of hypersensitivity/anaphylaxis and cardiac dysrhythmia with neuromuscular blockade reversal agent are focus of FDA advisory committee review.
Is Fabre-Kramer’s Gepirone Antidepressant Rising From The Dead After 8 Years?
Nothing has been heard about the major depressive disorder treatment since FDA issued a third “not approvable” letter in 2007; advisory committee to discuss NDA in December.